Beliefs about and confidence in new medical treatments: lessons from COVID-19 vaccines

Not Applicable

Completed

• Conditions: Beliefs about and confidence in new medical treatments; Not Applicable

• Registration Number: ISRCTN14065615
• Lead Sponsor: niversity of Tokyo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-06
• Study Completion: 2022-11-24
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 15000

Inclusion Criteria

A non-probability sample of 15,000 respondents through a survey company, Rakuten Insight, Ltd, including participants of the past three survey waves

Exclusion Criteria

Respondents who do not give informed consent at the top page of the internet survey

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Self-reported subjective cost of/confidence in vaccination measured using a background characteristics survey when the participant responded to the survey between 01/11/2022 and 15/11/2022<br> 2. Self-reported history of taking up COVID-19 vaccines measured using a background characteristics survey when the participant responded to the survey between 01/11/2022 and 15/11/2022<br> 3. Impact of side effects on beliefs about vaccines, and through them, confidence in vaccination, and how long the change in confidence in vaccination sustains, measured using the results of this background characteristics survey and those implemented in 01/11/2022 and 15/11/2022<br> 4. Marginal means (probability) of wanting to take the next dose of a COVID-19 vaccine, of being confident in vaccination, and of being confident in science, measured when the participant responded to the survey between 01/11/2022 and 15/11/2022<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Hypothetical vaccination conditions under which the costs of taking up vaccines vary and respondents’ preferred conditions measured using a fully randomized conjoint experimental design when the participant responded to the survey between 01/11/2022 and 15/11/2022<br> 2. Experiences of COVID-19 arm” symptoms measured using a background characteristics survey when the participant responded to the survey between 01/11/2022 and 15/11/2022<br>